Your institution may have access to this item. Find your institution then sign in to continue.
Title
Maraviroc.
Authors
Kuritzkes, Daniel; Kar, Santwana; Kirkpatrick, Peter
Abstract
Maraviroc (Selzentry; Pfizer) is a small-molecule drug that inhibits HIV-1 entry by blocking the interaction between HIV-1 and the chemokine receptor CCR5 on host cells. It became the first drug in its class to be approved by the US FDA for the treatment of patients with CCR5-tropic HIV-1 in combination with other antiretroviral agents in August 2007, and it was approved in Europe (where its trade name is Celsentri) in September 2007.
Publication
Nature Reviews Drug Discovery, 2008, Vol 7, Issue 1, p15